<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-10T11:24:48Z</responseDate>
  <request identifier="oai:figshare.com:article/34036169" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/34036169</identifier>
        <datestamp>2026-09-30T17:44:49Z</datestamp>
        <setSpec>category_7</setSpec>
        <setSpec>category_12</setSpec>
        <setSpec>category_21</setSpec>
        <setSpec>category_46</setSpec>
        <setSpec>category_64</setSpec>
        <setSpec>category_132</setSpec>
        <setSpec>category_134</setSpec>
        <setSpec>portal_5</setSpec>
        <setSpec>item_type_1</setSpec>
        <setSpec>month_year_09_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>&lt;p&gt;Primary keratinocytes demonstrate dose-dependent gene induction via IFNγ-treatment.&lt;/p&gt;</dc:title>
          <dc:creator>Angelina Zimenko (25145435)</dc:creator>
          <dc:creator>Ian Hayman (25145438)</dc:creator>
          <dc:creator>Youyi Fong (519951)</dc:creator>
          <dc:creator>Luke D. Monroe (5165948)</dc:creator>
          <dc:creator>Margaret G. Mills (3756298)</dc:creator>
          <dc:creator>Alex Greninger (11084570)</dc:creator>
          <dc:creator>Christine Johnston (375038)</dc:creator>
          <dc:creator>Lawrence Corey (140058)</dc:creator>
          <dc:creator>Jia Zhu (135506)</dc:creator>
          <dc:subject>Medicine</dc:subject>
          <dc:subject>Cell Biology</dc:subject>
          <dc:subject>Biotechnology</dc:subject>
          <dc:subject>Immunology</dc:subject>
          <dc:subject>Cancer</dc:subject>
          <dc:subject>Infectious Diseases</dc:subject>
          <dc:subject>Virology</dc:subject>
          <dc:subject>strongly induced gene</dc:subject>
          <dc:subject>protein levels compared</dc:subject>
          <dc:subject>limited genital lesions</dc:subject>
          <dc:subject>infects genital epithelia</dc:subject>
          <dc:subject>increased nuclear localization</dc:subject>
          <dc:subject>including robust induction</dc:subject>
          <dc:subject>ifn &amp;# 947</dc:subject>
          <dc:subject>enhanced chemokine production</dc:subject>
          <dc:subject>immune cell recruitment</dc:subject>
          <dc:subject>epithelial antiviral defense</dc:subject>
          <dc:subject>antiviral immune cells</dc:subject>
          <dc:subject>asymptomatic viral shedding</dc:subject>
          <dc:subject>doses much lower</dc:subject>
          <dc:subject>cell cytokine signaling</dc:subject>
          <dc:subject>epithelial cells</dc:subject>
          <dc:subject>efficient recruitment</dc:subject>
          <dc:subject>either asymptomatic</dc:subject>
          <dc:subject>wide spectrum</dc:subject>
          <dc:subject>vaccine strategies</dc:subject>
          <dc:subject>understanding variability</dc:subject>
          <dc:subject>symptomatic donors</dc:subject>
          <dc:subject>results suggest</dc:subject>
          <dc:subject>results revealed</dc:subject>
          <dc:subject>recurrent self</dc:subject>
          <dc:subject>previously reported</dc:subject>
          <dc:subject>interferon gamma</dc:subject>
          <dc:subject>improving therapies</dc:subject>
          <dc:subject>clinical outcomes</dc:subject>
          <dc:subject>chemokines involved</dc:subject>
          <dc:description>&lt;p&gt;&lt;b&gt;(A)&lt;/b&gt; Changes of &lt;i&gt;CXCL10, CCL5, IL15, IL12A&lt;/i&gt;, and &lt;i&gt;IFI16&lt;/i&gt; expression in primary keratinocytes (n = 10 donors with 3 replicates per donor, A-C) 4 hours following mock-treatment or treatment with 0.1, 1.0, 10, or 100 U/mL IFNγ, normalized to β-actin (dashed line). Data is represented as ΔCt, which is calculated by subtracting the Ct value of β-actin from the Ct of induced genes. All Ct values were acquired directly from qPCR with a maximum Ct threshold of 35. &lt;b&gt;(B)&lt;/b&gt; Fold change in &lt;i&gt;CXCL10, CCL5, IL15, IL12A&lt;/i&gt;, and &lt;i&gt;IFI16&lt;/i&gt; expression in primary keratinocytes (n = 10) 4 hours following mock-treatment or treatment with 0.1, 1.0, 10, or 100 U/mL IFNγ. Fold change is calculated as relative to mock expression, normalized to β-actin, using the ΔΔCt method. The bold line represents the average fold change of gene expression across all donors. Dashed lines represent fold change expression in individual donors. &lt;b&gt;(C)&lt;/b&gt; Fold change in &lt;i&gt;CXCL10, CCL5, IL15, IL12A&lt;/i&gt;, and &lt;i&gt;IFI16&lt;/i&gt; expression in primary keratinocytes mock-treated or treated with 100 U/mL IFNγ at 4 hours and 24 hours post-treatment. Symbols represent the geometric mean of each individual donor. &lt;sup&gt;*&lt;/sup&gt;&lt;i&gt;P&lt;/i&gt; &lt; 0.05, &lt;sup&gt;**&lt;/sup&gt; &lt;i&gt;P&lt;/i&gt; &lt; 0.01, &lt;sup&gt;***&lt;/sup&gt; &lt;i&gt;P&lt;/i&gt; &lt; 0.001, NS, not significant; linear mixed models were used to analyze fold change in gene expression.&lt;/p&gt;</dc:description>
          <dc:date>2026-09-30T17:55:35Z</dc:date>
          <dc:type>Image</dc:type>
          <dc:type>Figure</dc:type>
          <dc:identifier>10.1371/journal.ppat.1014612.g002</dc:identifier>
          <dc:relation>https://figshare.com/articles/figure/_p_Primary_keratinocytes_demonstrate_dose-dependent_gene_induction_via_IFN_-treatment_p_/34036169</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
